Search
Research
Preoperative preparation of children with upper respiratory tract infection: a focussed narrative reviewThis review summarises the current evidence for the perioperative preparation in children with upper respiratory tract infections (URTI), including COVID-19 infection. URTI, including COVID-19 infection, are common and frequent in children who present for elective surgery. Children with URTI are at increased risk of perioperative respiratory adverse events.
Research
Cord-blood respiratory syncytial virus antibodies and respiratory health in first 5 years of lifeTo determine the potential longer-term effects of maternal antenatal respiratory syncytial virus (RSV) vaccination, we examined the association between cord-blood RSV-neutralizing antibodies (RSV-NA) and RSV infections in the first 2 years of life, RSV-NA at 3 years, and respiratory health to age 5 years.
Research
Factors Predicting Secondary Respiratory Morbidity Following Early-Life Respiratory Syncytial Virus Infections: Population-Based Cohort StudyThe association between early-life respiratory syncytial virus infections and later respiratory morbidity is well established. However, there is limited evidence on factors that influence this risk. We examined sociodemographic and perinatal factors associated with later childhood respiratory morbidity requiring secondary care following exposure to a laboratory-confirmed RSV episode in the first 2 years.
Research
Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trialsAustralian First Nations children are at very high risk of early, recurrent, and persistent bacterial otitis media and respiratory tract infection. With the PREVIX randomised controlled trials, we aimed to evaluate the immunogenicity of novel pneumococcal conjugate vaccine (PCV) schedules.
Research
Characterising the epidemiology of RSV in Australian children through record linkage: clinical burden, outcomes and risk factorsHannah Peter Moore Richmond OAM BSc (Hons) GradDipClinEpi PhD MBBS MRCP(UK) FRACP Head, Infectious Diseases Research Head, Vaccine Trials Group 08
News & Events
RSV responsible for one out of every 50 childhood deaths worldwideThe urgency for a world-first respiratory syncytial virus vaccine is at an all-time high.
News & Events
Global study finds human air travel culprit for RSV variant spreadGlobal circulation of respiratory syncytial virus (RSV) is shaped by human air travel with travellers hosting new strains fuelling transmission across borders, an international The Kids Research Institute Australia study found.
News & Events
RSV vaccine for pregnant women provides protection for babies: studyA world-first study has found a new vaccine against potentially deadly respiratory syncytial virus (RSV) is safe and effective for use in pregnant women, to help protect their babies.
News & Events
RSV prevention finally in reach after 20 years of research at The Kids Research Institute AustraliaWorld-first immunisations providing protection against deadly respiratory syncytial virus (RSV) could be just months away thanks to global research efforts spanning multiple decades.
Research
Who is at risk of a respiratory syncytial virus hospitalisation? A linked, population-based birth cohort analysis in children aged less than 5 yearsRespiratory syncytial virus (RSV) is a major cause of acute lower respiratory infections globally in children under five years. With the development of RSV prevention strategies, understanding risk factors and relation to age and population is useful for deciding the type of program implemented.